Clinical efficacy of valsartan combined with atorvastatin on patients with diabetic nephropathy
10.13699/j.cnki.1001-6821.2015.03.004
- VernacularTitle:缬沙坦联合阿托伐他汀治疗早期糖尿病肾病的临床研究
- Author:
Yi-Fei LIAO
1
;
Bin-Bin FU
;
Zhi-Hong GUI
;
Le-Jian LAN
;
Wei-Hai XU
;
Mei-Juan XIANG
Author Information
1. 温州医学院 附属第六医院 肾内科
- Keywords:
diabetic nephropathy;
valsartan;
atorvastatin;
clinical efficacy
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):172-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect and safety of valsartan combined with atorvastatin in the treatment of early stage diabetic nephropathy ( DN).Methods Sixty-three patients with early stage DN were recruited in this study and divided into two groups.The patients in experiment group ( n =30 ) were given valsartan 80 mg· d -1 combined with atorvastatin 20 mg · d -1 , and the control group ( n =33 ) were only given valsartan treatment.The treatment lasted for 4 months.After treatment, the data of serum level of serum creatinine ( Scr) , urinary albumin excretion rate ( UAER) , glomeru-lar filtration rate ( GFR ) and β2 -microglobulin (β2 -MG ) were compared between the two groups.Results After 4 -month treat-ment, the serum Scr, UAER and β2 -MG were decreased in both groups ( P<0.05 ) , but the changes in experiment group was much more significant than that in control group ( P<0.05 ).The adverse reactions such as cough, headache and dizziness were not statistically different between the two groups ( P<0.05 ).Conclusion Valsar-tan combined with atorvastatin treatment can improve the clinical efficacy in the treatment of diabetic nephropathy, without increasing adverse reactions.
